Page 7 - Alkermes News Today

Fuller & Thaler Asset Management Inc. boosted its stake in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 8.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 412,822 shares of the company’s stock after acquiring an additional 33,089 shares during the period. Fuller & Thaler […]

Fuller & Thaler Asset Management Inc. grew its position in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 8.7% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 412,822 shares of the company’s stock after acquiring an additional 33,089 shares during the period. Fuller & Thaler Asset Management Inc.’s holdings in Alkermes […]

Jason Gerberry, an analyst from Bank of America Securities, reiterated the Sell rating on Bausch Health Companies (BHC – Research Report)....

Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 256.7% during the third quarter, HoldingsChannel reports. The firm owned 271,100 shares of the company’s stock after buying an additional 195,100 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Alkermes […]

Healthcare of Ontario Pension Plan Trust Fund raised its holdings in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 256.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 271,100 shares of the company’s stock after purchasing an additional 195,100 […]

HRMY earnings call for the period ending December 31, 2023.

HRMY earnings call for the period ending December 31, 2023.

Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average […]

Catalyst-rich 2024 with multiple clinical data readouts and updates expected for pipeline and discovery programs Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer...

DUBLIN--(BUSINESS WIRE)--The "Modified Release Neurology Therapeutics" report has been added to ResearchAndMarkets.com's offering.Large pharmaceutical and biotechnology companies are increasingly pursuing in-licensing to offset lower than expected drug development productivity and surging research costs. Data mining...